TEL AVIV, Israel--(BUSINESS WIRE)--Tikcro Technologies Ltd. (OTCBB: TIKRF) today reported that BioCancell Therapeutics, Inc. announced that a compassionate use trial of BC-819 was performed with a single patient in Israel suffering from TCC (Transitional Cell Carcinoma) in his renal pelvis.
